What non‑opioid pharmacologic options can be used to reduce respiratory distress?

Non-Opioid Options for Respiratory Distress

For respiratory distress refractory to treatment of underlying causes, benzodiazepines (when anxiety is present), anticholinergics for secretions, supplemental oxygen (if hypoxemic), and handheld fans directed at the face are the primary non-opioid pharmacologic and non-pharmacologic options, though the evidence base for non-opioids remains limited compared to opioids.

Pharmacologic Non-Opioid Options

Benzodiazepines

• Use selectively for dyspnea associated with anxiety 1
• The beneficial effect on dyspnea in advanced cancer patients is small 1
• Evidence shows no benefit as primary treatment for breathlessness in cancer or COPD patients 2
• Conditional recommendation (70.7% expert consensus): Consider benzodiazepines when patients are very distressed or anxious, when opioids have insufficient effect, when opioids are contraindicated, or in the last days of life 2
• Important caveat: A Cochrane review found no evidence supporting benzodiazepines for breathlessness, but they may be considered when non-pharmacological measures and opioids fail, particularly with concurrent distress and anxiety 2

Anticholinergic Agents for Secretions

When dyspnea is associated with excessive secretions 1:

• Glycopyrrolate (preferred): Does not cross blood-brain barrier effectively, less likely to cause delirium, though anticholinergic side effects still occur
• Scopolamine: Subcutaneous or transdermal routes available
  • Critical timing issue: Transdermal patches have 12-hour onset—inappropriate for imminently dying patients
  • Subcutaneous injection can be given when patch is applied or if secretion management is inadequate
• Atropine and hyoscyamine: Alternative options

Other Pharmacologic Agents

• Bronchodilators, diuretics, steroids, antibiotics: Treat underlying comorbid conditions contributing to dyspnea 1
• Nebulized furosemide: Insufficient evidence to recommend; majority of studies in asthma patients, small COPD studies showed some benefit, but a cancer trial showed no benefit 3
• Anxiolytics, antidepressants, phenothiazines, indomethacin: Found ineffective or lack sufficient data 3

Non-Pharmacologic Interventions

Handheld Fan (Strong Evidence)

• Randomized controlled crossover trial demonstrated breathlessness reduction when directed at the face 1
• Simple, safe, no cost, easy to implement

Supplemental Oxygen

• Strong recommendation (57.4%) for oxygen when SpO2 <90% 2
• Evidence is conflicting for symptomatic relief 4
• Key finding: Randomized trial showed dyspnea scores were no different between palliative oxygen versus room air in patients with refractory dyspnea 1
• No benefit from oxygen compared to medical air in advanced lung disease patients who were not hypoxemic 4
• Patients near death remained comfortable without oxygen 4
• Use oxygen primarily for hypoxemia correction rather than symptom management alone

Noninvasive Positive-Pressure Ventilation (NIV)

• More effective than oxygen in reducing dyspnea in patients with solid tumors and respiratory failure, particularly with hypercarbia 4
• 7% discontinued due to intolerance 4
• Feasibility study showed BiPAP improved dyspnea symptoms and required lower opioid doses compared to oxygen alone 1
• However, a phase II trial comparing high-flow oxygen to BiPAP showed no significant differences 1
• Consider for acute respiratory failure in appropriate candidates, but effectiveness for pure symptom palliation is less established

Treatment Algorithm

1. First: Treat underlying causes

   • Cardiac/pleural/abdominal fluid drainage
   • Bronchoscopic therapy
   • Bronchodilators for bronchospasm
   • Diuretics for fluid overload
   • Antibiotics for infection
   • Anticoagulants for pulmonary emboli 1

2. If hypoxemic (SpO2 <90%)

   • Provide supplemental oxygen 2
   • Consider NIV if appropriate candidate 4, 1

3. If excessive secretions present

   • Glycopyrrolate (first choice to minimize delirium risk)
   • Scopolamine subcutaneous (for rapid effect) or transdermal (if >12 hours expected survival) 1

4. If anxiety is prominent component

   • Trial of benzodiazepines 1, 2
   • Titrate to effect

5. Always implement

   • Handheld fan directed at face 1

Critical Evidence Gaps

The evidence for non-opioid treatments of chronic breathlessness is substantially weaker than for opioids 5, 6. Multiple systematic reviews conclude:

• Insufficient evidence to recommend routine use of non-opioid medications 5, 6
• Morphine still has the best level of evidence for symptomatic treatment of chronic breathlessness 5
• Further randomized controlled trials are needed 1

Common Pitfalls

• Assuming oxygen always helps dyspnea: Oxygen benefits hypoxemia but may not relieve breathlessness in non-hypoxemic patients 4, 1
• Using transdermal scopolamine in imminently dying patients: 12-hour onset makes this inappropriate; use subcutaneous route instead 1
• Expecting benzodiazepines to work as primary dyspnea treatment: Evidence shows minimal benefit unless anxiety is a significant component 1, 2
• Overlooking simple interventions: Handheld fans have solid RCT evidence and are often forgotten 1